Inhibition of TGF-β-related factors or NLRP3 inflammasome may play an important role in breaking the vicious cycle and are recommended as therapeutic targets for the progression and treatment of liver fibrosis. This evidence concerns the gene NLRP3 and Hepatic fibrosis.